Background The aim of the present study was to estimate the cost-effectiveness of populationwide approaches to reduce serum cholesterol levels in the US adult population.
Methods and Results This cost-effectiveness analysis was made from data from the literature and the Coronary Heart Disease Policy Model and was based on the US population age 35 to 84 years.
Study interventions were populationwide programs to reduce serum cholesterol levels with costs and cholesterol-lowering effects similar to those reported from the Stanford Three-Community Study, the Stanford Five-City Project, and in North Karelia, Finland.
The main outcome measures were cost-effectiveness ratios, defined as the change in projected cost divided by the change in projected life-years when the population receives the intervention compared with the population without the intervention.
A populationwide program with the costs ($4.95 per person per year) and cholesterol-lowering effects (an average 2% reduction in serum cholesterol levels) of the Stanford Five-City Project would prolong life at an estimated cost of only $3200 per year of life saved.
Under a wide variety of assumptions, a populationwide program would achieve health benefits at a cost equivalent to that of many currently accepted medical interventions. (...)
Mots-clés Pascal : Cardiopathie coronaire, Hypercholestérolémie, Hypolipémiant, Cholestérol, Sérum, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Prévention, Homme, Lipide, Appareil circulatoire pathologie, Métabolisme pathologie, Dyslipémie, Hyperlipoprotéinémie
Mots-clés Pascal anglais : Coronary heart disease, Hypercholesterolemia, Antilipemic agent, Cholesterol, Serum, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Prevention, Human, Lipids, Cardiovascular disease, Metabolic diseases, Dyslipemia, Hyperlipoproteinemia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0142639
Code Inist : 002B02N. Création : 21/05/1997.